Nonetheless, there is still a lack of reference data on several aspects of SMA’s natural history, including lung function, but obtaining additional ‘treatment-naïve’ patient data has become increasingly difficult now that SMN2-antisense oligonucleotide treatment is reimbursed in many countries [9]. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.